Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges: 2022-2025

Historic Amortization of Deferred Charges for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to $1.2 million.

  • Phathom Pharmaceuticals' Amortization of Deferred Charges rose 15.93% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 25.03%. This contributed to the annual value of $3.8 million for FY2024, which is 5.36% up from last year.
  • Phathom Pharmaceuticals' Amortization of Deferred Charges amounted to $1.2 million in Q3 2025, which was up 1.73% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Amortization of Deferred Charges registered a high of $1.2 million during Q3 2025, and its lowest value of $806,000 during Q1 2024.
  • For the 3-year period, Phathom Pharmaceuticals' Amortization of Deferred Charges averaged around $985,182, with its median value being $912,000 (2023).
  • Per our database at Business Quant, Phathom Pharmaceuticals' Amortization of Deferred Charges dropped by 8.10% in 2024 and then soared by 41.56% in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Amortization of Deferred Charges (Quarterly) stood at $890,000 in 2022, then climbed by 1.01% to $899,000 in 2023, then climbed by 16.91% to $1.1 million in 2024, then grew by 15.93% to $1.2 million in 2025.
  • Its Amortization of Deferred Charges stands at $1.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.1 million for Q1 2025.